DASH vs ESPR · P/E 76, rev $13.72B vs rev $332.3M
DoorDash, Inc. Class A Common Stock (DASH) versus Esperion Therapeutics Inc (ESPR) — a side-by-side from cached financials, not a winner call.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
DASH currently screens at market cap $69.41B and trailing P/E 75.9. ESPR currently screens at market cap $816.9M.
Not investment advice. Open the DASH and ESPR stock pages for the full models.
Not investment advice.